NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study

2015129 citationsJournal Articlehybrid Open Access

Authors

Christopher O’Brien · Neurocrine Biosciences (United States)

Roland Jimenez · Neurocrine Biosciences (United States)

Robert A. Hauser · University of South Florida

Stewart A. Factor · Emory University

Joshua Burke · Neurocrine Biosciences (United States)

Daniel Mandri · St. Thomas University

Julio C. Castro‐Gayol

Abstract

NBI-98854 significantly improved tardive dyskinesia and was well tolerated in patients. These results support the phase 3 clinical trials of NBI-98854 now underway.

Topics & Keywords

Schizophrenia research and treatment Bipolar Disorder and Treatment Parkinson's Disease Mechanisms and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Movement Disorders

Volume 30, Issue 12, pp. 1681-1687

DOI: 10.1002/mds.26330

Field-Weighted Citation Impact: 10.96